1. |
Shiraya T, Araki F, Nakagawa S, et al. Differential gene expression analysis using RNA sequencing: retinal pigment epithelial cells after exposure to continuous-wave and subthreshold micropulse laser[J]. Jpn J Ophthalmol, 2022, 66(5): 487-497. DOI: 10.1007/s10384-022-00925-0.
|
2. |
Van Rijssen TJ, Van Dijk EHC, Yzer S, et al. Central serous chorioretinopathy: towards an evidence-based treatment guideline[J/OL]. Prog Retin Eye Res, 2019, 73: 100770[2019-07-15]. https://linkinghub.elsevier.com/retrieve/pii/S1350-9462(18)30094-6. DOI:10.1016/j.preteyeres.2019.07.003.
|
3. |
Spaide RF, Gemmy Cheung CM, Matsumoto H, et al. Venous overload choroidopathy: a hypothetical framework for central serous chorioretinopathy and allied disorders[J/OL]. Prog Retin Eye Res, 2022, 86: 100973[2021-05-21]. https://linkinghub.elsevier.com/retrieve/pii/S1350-9462(21)00034-3. DOI:10.1016/j.preteyeres.2021.100973.
|
4. |
Prasuhn M, Miura Y, Tura A, et al. Influence of retinal microsecond pulse laser treatment in central serous chorioretinopathy: a short-term qptical coherence tomography angiography study[J]. J Clin Med, 2021, 10(11): 2418. DOI: 10.3390/jcm10112418.
|
5. |
Mainster MA. Wavelength selection in macular photocoagulation. Tissue optics, thermal effects, and laser systems[J]. Ophthalmology, 1986, 93(7): 952-958. DOI: 10.1016/s0161-6420(86)33637-6.
|
6. |
Feenstra HMA, Hahn LC, Van Rijssen TJ, et al. Efficacy of half-dose photodynamic therapy versus high-density subthreshold micropulse laser for treating pigment epithelial detachments in chronic central serous chorioretinopathy[J]. Retina, 2022, 42(4): 721-729. DOI: 10.1097/IAE.0000000000003363.
|
7. |
Van Dijk EHC, Fauser S, Breukink MB, et al. Half-dose photodynamic therapy versus high-density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy: the PLACE trial[J]. Ophthalmology, 2018, 125(10): 1547-1555. DOI: 10.1016/j.ophtha.2018.04.021.
|
8. |
Van Rijssen TJ, Van Dijk EHC, Scholz P, et al. Focal and diffuse chronic central serous chorioretinopathy treated with half-dose photodynamic therapy or subthreshold micropulse laser: PLACE trial report No. 3[J]. Am J Ophthalmol, 2019, 205: 1-10. DOI: 10.1016/j.ajo.2019.03.025.
|
9. |
Chang DB, Luttrull JK. Comparison of subthreshold 577 and 810 nm micropulse laser effects on heat-shock protein activation kinetics: implications for treatment efficacy and safety[J]. Transl Vis Sci Technol, 2020, 9(5): 23. DOI: 10.1167/tvst.9.5.23.
|
10. |
Sun Z, Huang Y, Nie C, et al. Efficacy and safety of subthreshold micropulse laser compared with threshold conventional laser in central serous chorioretinopathy[J]. Eye (Lond), 2020, 34(9): 1592-1599. DOI: 10.1038/s41433-019-0692-8.
|
11. |
Zhou L, Lai K, Jin L, et al. Subthreshold micropulse laser vs. conventional laser for central serous chorioretinopathy: a randomized controlled clinical trial[J/OL]. Front Med (Lausanne), 2021, 8: 682264[2021-07-16]. https://europepmc.org/article/MED/34336888. DOI:10.3389/fmed.2021.682264.
|
12. |
Altınel MG, Acikalin B, Gunes H, et al. Optical coherence tomography parameters as predictors of treatment response to a 577-nm subthreshold micropulse laser in chronic central serous chorioretinopathy[J]. Lasers Med Sci, 2021, 36(7): 1505-1514. DOI: 10.1007/s10103-020-03225-6.
|
13. |
Uzlu D, Erdöl H, Kola M, et al. The efficacy of subthreshold micropulse yellow laser (577 nm) in chronic central serous chorioretinopathy[J]. Lasers Med Sci, 2021, 36(5): 981-988. DOI: 10.1007/s10103-020-03129-5.
|
14. |
Huang Y, Zheng W, Sun Z, et al. Optical coherence tomography biomarkers as predictors of transition to chronic central serous chorioretinopathy after retinal laser photocoagulation[J/OL]. Ther Adv Chronic Dis, 2023, 14: 20406223221146720[2023-01-21]. https://europepmc.org/article/MED/36704642. DOI:10.1177/20406223221146721.
|
15. |
Malik KJ, Sampat KM, Mansouri A, et al. Low-intensity/high-density subthreshold micropulse diode laser for chronic central serous chorioretinopathy[J]. Retina, 2015, 35(3): 532-536. DOI: 10.1097/IAE.0000000000000285.
|
16. |
Yadav NK, Jayadev C, Mohan A, et al. Subthreshold micropulse yellow laser (577 nm) in chronic central serous chorioretinopathy: safety profile and treatment outcome[J]. Eye (Lond), 2015, 29(2): 258-264; quiz 265. DOI:10.1038/eye.2014.315.
|
17. |
Ho M, Lai FHP, Ng DSC, et al. Analysis of choriocapillaris perfusion and choroidal layer changes in patients with chronic central serous chorioretinopathy randomised to micropulse laser or photodynamic therapy[J]. Br J Ophthalmol, 2021, 105(4): 555-560. DOI: 10.1136/bjophthalmol-2020-316076.
|
18. |
Kiraly P, Smrekar J, Jaki Mekjavić P. Morphological parameters predicting subthreshold micropulse laser effectiveness in central serous chorioretinopathy[J]. Lasers Med Sci, 2022, 37(8): 3129-3136. DOI: 10.1007/s10103-022-03574-4.
|
19. |
Keunen JEE, Battaglia-Parodi M, Vujosevic S, et al. International retinal laser society guidelines for subthreshold laser treatment[J]. Transl Vis Sci Technol, 2020, 9(9): 15. DOI: 10.1167/tvst.9.9.15.
|
20. |
Chhablani J, SOLS (Subthreshold Laser Ophthalmic Society) Writing Committee. Subthreshold laser therapy guidelines for retinal diseases[J]. Eye (Lond), 2022, 36(12): 2234-2235. DOI: 10.1038/s41433-022-02136-w.
|
21. |
Işık MU, Değirmenci MFK, Sağlık A. Efficacy of the subthreshold micropulse yellow wavelength laser photostimulation in the treatment of chronic central serous chorioretinopathy[J]. Int J Ophthalmol, 2020, 13(9): 1404-1410. DOI: 10.18240/ijo.2020.09.11.
|
22. |
Zhou L, Chong V, Lai K, et al. A pilot prospective study of 577-nm yellow subthreshold micropulse laser treatment with two different power settings for acute central serous chorioretinopathy[J]. Lasers Med Sci, 2019, 34(7): 1345-1351. DOI: 10.1007/s10103-019-02721-8.
|
23. |
Yenari MA, Liu J, Zheng Z, et al. Antiapoptotic and anti-inflammatory mechanisms of heat-shock protein protection[J]. Ann N Y Acad Sci, 2005, 1053: 74-83. DOI: 10.1196/annals.1344.007.
|
24. |
Kern K, Mertineit CL, Brinkmann R, et al. Expression of heat shock protein 70 and cell death kinetics after different thermal impacts on cultured retinal pigment epithelial cells[J]. Exp Eye Res, 2018, 170: 117-126. DOI: 10.1016/j.exer.2018.02.013.
|
25. |
Hirabayashi K, Kakihara S, Tanaka M, et al. Investigation of the therapeutic mechanism of subthreshold micropulse laser irradiation in retina[J]. Graefe's Arch Clin Exp Ophthalmol, 2020, 258(5): 1039-1047. DOI: 10.1007/s00417-020-04638-3.
|
26. |
De Cillà S, Vezzola D, Farruggio S, et al. The subthreshold micropulse laser treatment of the retina restores the oxidant/antioxidant balance and counteracts programmed forms of cell death in the mice eyes[J]. Acta Ophthalmol, 2019, 97(4): 559-567. DOI: 10.1111/aos.13995.
|
27. |
Gawęcki M, Jaszczuk A, Grzybowski A. Short term presence of subretinal fluid in central serous chorioretinopathy affects retinal thickness and function[J]. J Clin Med, 2020, 9(11): E3429. DOI: 10.3390/jcm9113429.
|
28. |
Li X, Long H, Hu Q. Efficacy of subthreshold micropulse laser for chronic central serous chorioretinopathy: a meta-analysis[J/OL]. Photodiagnosis Photodyn Ther, 2022, 39: 102931[2022-05-27]. https://linkinghub.elsevier.com/retrieve/pii/S1572-1000(22)00217-4. DOI:10.1016/j.pdpdt.2022.102931.
|
29. |
Van Rijssen TJ, Van Dijk EHC, Scholz P, et al. Long-term follow-up of chronic central serous chorioretinopathy after successful treatment with photodynamic therapy or micropulse laser[J]. Acta Ophthalmol, 2021, 99(7): 805-811. DOI: 10.1111/aos.14775.
|
30. |
Van Rijssen TJ, Van Dijk EHC, Scholz P, et al. Crossover to photodynamic therapy or micropulse laser after failure of primary treatment of chronic central serous chorioretinopathy: the REPLACE trial[J]. Am J Ophthalmol, 2020, 216: 80-89. DOI: 10.1016/j.ajo.2020.04.007.
|
31. |
Călugăru D, Călugăru M. Re: van Dijk et al: half-dose photodynamic therapy versus high-density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy: the PLACE trial (Ophthalmology. 2018;125: 1547-1555)[J]. Ophthalmology, 2019, 126(1): 10-11. DOI: 10.1016/j.ophtha.2018.06.037.
|
32. |
Battaglia Parodi M, Iacono P. Re: van Dijk et al. : half-dose photodynamic therapy versus high-density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy: the PLACE trial (Ophthalmology. 2018;125: 1547-1555)[J]. Ophthalmology, 2019, 126(4): 29-30. DOI: 10.1016/j.ophtha.2018.11.004.
|
33. |
Wu L, Roca JA. Comment on: crossover to photodynamic thrapy or micropulse laser after failure of primary treatment of chronic central serous chorioretinopathy[J]. Am J Ophthalmol, 2021, 222: 397. DOI: 10.1016/j.ajo.2020.09.052.
|
34. |
Luttrull JK. Comment on: Focal and diffuse chronic central serous chorioretinopathy treated with half-dose photodynamic therapy or subthreshold micropulse laser: PLACE trial report No. 3[J]. Am J Ophthalmol, 2020, 212: 186-187. DOI: 10.1016/j.ajo.2019.10.037.
|
35. |
Van Rijssen TJ, Van Dijk EHC, Dijkman G, et al. Reply to comment on: crossover to photodynamic therapy or micropulse laser after failure of primary treatment of chronic central serous chorioretinopathy[J]. Am J Ophthalmol, 2021, 222: 397-398. DOI: 10.1016/j.ajo.2020.10.005.
|